

Andrés F. Muro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7002435/publications.pdf>

Version: 2024-02-01

84
papers

3,804
citations

147801

31
h-index

128289

60
g-index

86
all docs

86
docs citations

86
times ranked

4808
citing authors

#	ARTICLE	IF	CITATIONS
1	Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. <i>Frontiers in Genome Editing</i> , 2022, 4, 785698.	5.2	8
2	Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice. <i>Nature Biotechnology</i> , 2022, 40, 1285-1294.	17.5	8
3	Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 169-180.	4.1	12
4	Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 287-297.	4.1	9
5	Low efficacy of recombinant SV40 in <i>Ugt1a1</i> ^{-/-} mice with severe inherited hyperbilirubinemia. <i>PLoS ONE</i> , 2021, 16, e0250605.	2.5	0
6	Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders. <i>EMBO Molecular Medicine</i> , 2021, 13, e13158.	6.9	16
7	Long-Term Effects of Biliverdin Reductase a Deficiency in <i>Ugt1a1</i> ^{+/+} Mice: Impact on Redox Status and Metabolism. <i>Antioxidants</i> , 2021, 10, 2029.	5.1	3
8	Experimental models assessing bilirubin neurotoxicity. <i>Pediatric Research</i> , 2020, 87, 17-25.	2.3	14
9	A Quantitative In Vitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 250-258.	4.1	9
10	Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice. <i>Scientific Reports</i> , 2020, 10, 887.	3.3	11
11	Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 157-174.	4.1	45
12	Gene Therapy in Pediatric Liver Disease. , 2019, , 799-829.		2
13	EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. <i>Journal of Experimental Medicine</i> , 2019, 216, 587-604.	8.5	36
14	Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. <i>JCI Insight</i> , 2019, 4, .	5.0	28
15	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 166-178.	4.1	39
16	Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy. <i>Haematologica</i> , 2018, 103, e42-e45.	3.5	4
17	Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-11.	4.0	41
18	Advances in understanding disease mechanisms and potential treatments for Crigler-Najjar syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 425-439.	0.8	17

#	ARTICLE	IF	CITATIONS
19	EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. <i>Blood</i> , 2018, 132, 1781-1781.	1.4	3
20	Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I. <i>Gene Therapy</i> , 2017, 24, 649-660.	4.5	27
21	Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model. <i>EMBO Molecular Medicine</i> , 2017, 9, 1346-1355.	6.9	46
22	Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1 -/- mouse model. <i>Journal of Neuroinflammation</i> , 2017, 14, 64.	7.2	34
23	Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes. <i>Scientific Reports</i> , 2016, 6, 37965.	3.3	17
24	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in the Ugt1-/- lethal mouse model of neonatal hyperbilirubinemia. <i>Human Molecular Genetics</i> , 2016, 26, ddw375.	2.9	13
25	158. Cryptic ATG Removal from Synthetic Introns Increase the Therapeutic Efficacy of AAV Vector Mediated Gene Transfer. <i>Molecular Therapy</i> , 2016, 24, S62.	8.2	1
26	Absence of fibronectin-EDA contributes to sepsis outcomes in a murine model. <i>Atherosclerosis</i> , 2016, 252, e179.	0.8	1
27	A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16049.	4.1	50
28	Brief Report: Alternative Splicing of Extra Domain A (EIIIA) of Fibronectin Plays a Tissue-Specific Role in Hematopoietic Homeostasis. <i>Stem Cells</i> , 2016, 34, 2263-2268.	3.2	9
29	547. Untranslated Region Optimization Increases Transgene mRNA and Protein Levels, Resulting in Enhanced Therapeutic Efficacy of AAV Vector Gene Transfer In Vivo for Crigler-Najjar Syndrome. <i>Molecular Therapy</i> , 2015, 23, S219-S220.	8.2	0
30	688. AAV8-Mediated Liver Gene Targeting Without Nucleases Rescues Lethality in a Mouse Model of the Crigler-Najjar Syndrome. <i>Molecular Therapy</i> , 2015, 23, S274.	8.2	0
31	704. Long-Term Correction of Crigler-Najjar Syndrome and Scale-Up Production of an Optimized AAV8 Vector Expressing the UGT1A1 Transgene. <i>Molecular Therapy</i> , 2015, 23, S280-S281.	8.2	0
32	Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia. <i>Scientific Reports</i> , 2015, 5, 16203.	3.3	22
33	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015, 114, 186-197.	3.4	21
34	Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice. <i>Cell Death and Disease</i> , 2015, 6, e1739-e1739.	6.3	33
35	TDP-43 regulates β -adducin transcript stability. <i>RNA Biology</i> , 2014, 11, 1280-1290.	3.1	40
36	Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicity in vivo. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 1057-68.	2.4	36

#	ARTICLE	IF	CITATIONS
37	Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Criglerâ€Najjar Syndrome. Human Gene Therapy, 2014, 25, 844-855.	2.7	74
38	Generation of Ugt1-Deficient Murine Liver Cell Lines Using TALEN Technology. PLoS ONE, 2014, 9, e104816.	2.5	11
39	Extra domain-A fibronectin is necessary for the development of nasal remodeling in chronic allergen-induced rhinitis. Annals of Allergy, Asthma and Immunology, 2013, 110, 322-327.	1.0	5
40	EMILIN1/Î±9Î²1 Integrin Interaction Is Crucial in Lymphatic Valve Formation and Maintenance. Molecular and Cellular Biology, 2013, 33, 4381-4394.	2.3	62
41	Characterization of the Distal Polyadenylation Site of the ÎŸ-Adducin (Add2) Pre-mRNA. PLoS ONE, 2013, 8, e58879.	2.5	8
42	Long-distance regulation of Add2 pre-mRNA3â€²end processing. RNA Biology, 2013, 10, 516-527.	3.1	3
43	EDA-Containing Fibronectin Increases Proliferation of Embryonic Stem Cells. PLoS ONE, 2013, 8, e80681.	2.5	21
44	Rescue of bilirubinâ€²induced neonatal lethality in a mouse model of Criglerâ€Najjar syndrome type I by AAV9â€²mediated gene transfer. FASEB Journal, 2012, 26, 1052-1063.	0.5	71
45	Identification of 3â€² gene ends using transcriptional and genomic conservation across vertebrates. BMC Genomics, 2012, 13, 708.	2.8	5
46	Recipientâ€²derived EDA fibronectin promotes cardiac allograft fibrosis. Journal of Pathology, 2012, 226, 609-618.	4.5	50
47	Stam2 expression pattern during embryo development. Gene Expression Patterns, 2012, 12, 68-76.	0.8	2
48	The extra domain Aâ€²of fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice. Journal of Allergy and Clinical Immunology, 2011, 127, 439-446.e5.	2.9	27
49	Extra Domain A Fibronectin Promotes Fibrotic Remodeling In Chronic Cardiac Allograft Rejection. , 2011,, .		0
50	Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life, 2011, 63, 538-546.	3.4	141
51	Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Experimental Cell Research, 2010, 316, 2644-2653.	2.6	59
52	Î²â€²adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the Î±â€²and Î³â€²adducin subunits. Genes, Brain and Behavior, 2010, 9, 84-96.	2.2	39
53	CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3â€²-UTRs. Nucleic Acids Research, 2010, 38, 7698-7710.	14.5	25
54	EDAâ€²containing cellular fibronectin induces fibroblast differentiation through binding to Î± ₄ Î² ₇ integrin receptor and MAPK/Erk 1/2â€²dependent signaling. FASEB Journal, 2010, 24, 4503-4512.	0.5	130

#	ARTICLE	IF	CITATIONS
55	Integrin-�9 Is Required for Fibronectin Matrix Assembly during Lymphatic Valve Morphogenesis. <i>Developmental Cell</i> , 2009, 17, 175-186.	7.0	290
56	New insights into form and function of fibronectin splice variants. <i>Journal of Pathology</i> , 2008, 216, 1-14.	4.5	288
57	Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. <i>Atherosclerosis</i> , 2008, 197, 534-540.	0.8	45
58	Prothrombotic Effects of Fibronectin Isoforms Containing the EDA Domain. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 296-301.	2.4	46
59	An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 638-645.	5.6	257
60	A Major Fraction of Fibronectin Present in the Extracellular Matrix of Tissues Is Plasma-derived. <i>Journal of Biological Chemistry</i> , 2007, 282, 28057-28062.	3.4	104
61	Unexpected Rescue of Alpha-synuclein and Multimerin1 Deletion in C57BL/6J OlaHsd Mice by Beta-adducin Knockout. <i>Transgenic Research</i> , 2006, 15, 255-259.	2.4	8
62	Brain-specific promoter and polyadenylation sites of the �-adducin pre-mRNA generate an unusually long 3'-UTR. <i>Nucleic Acids Research</i> , 2006, 34, 243-253.	14.5	201
63	A Polar Mechanism Coordinates Different Regions of Alternative Splicing within a Single Gene. <i>Molecular Cell</i> , 2005, 19, 393-404.	9.7	63
64	Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene. <i>Behavioural Brain Research</i> , 2005, 161, 31-38.	2.2	21
65	RNA Folding Affects the Recruitment of SR Proteins by Mouse and Human Polypurinic Enhancer Elements in the Fibronectin EDA Exon. <i>Molecular and Cellular Biology</i> , 2004, 24, 1387-1400.	2.3	106
66	An Exonic Splicing Enhancer Offsets the Atypical GU-rich 3�2 Splice Site of Human Apolipoprotein A-II Exon 3. <i>Journal of Biological Chemistry</i> , 2004, 279, 39331-39339.	3.4	15
67	Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. <i>Gene</i> , 2004, 324, 55-63.	2.2	32
68	The erythrocyte skeletons of �2-adducin deficient mice have altered levels of tropomyosin, tropomodulin and EcapZ. <i>FEBS Letters</i> , 2004, 576, 36-40.	2.8	17
69	Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. <i>Journal of Cell Biology</i> , 2003, 162, 149-160.	5.2	274
70	Hypertension-Linked Decrease in the Expression of Brain �3-Adducin. <i>Circulation Research</i> , 2002, 91, 633-639.	4.5	22
71	Hypertension in �2-Adducin��Deficient Mice. <i>Hypertension</i> , 2000, 36, 449-453.	2.7	37
72	Structural and Functional Analysis of the cAMP Binding Domain from the Regulatory Subunit of Mucor rouxii Protein Kinase A. <i>Archives of Biochemistry and Biophysics</i> , 2000, 382, 173-181.	3.0	4

#	ARTICLE	IF	CITATIONS
73	Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. , 1999, 82, 748-753.		17
74	Coupling of Transcription with Alternative Splicing. Molecular Cell, 1999, 4, 251-258.	9.7	274
75	Regulation of the human apolipoprotein AIV gene expression in transgenic mice. FEBS Letters, 1999, 445, 45-52.	2.8	9
76	Regulation of Fibronectin EDA Exon Alternative Splicing: Possible Role of RNA Secondary Structure for Enhancer Display. Molecular and Cellular Biology, 1999, 19, 2657-2671.	2.3	123
77	Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. , 1998, 78, 233-241.		16
78	Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5' splice site. FEBS Letters, 1998, 437, 137-141.	2.8	41
79	Characterisation and chromosomal localisation of the rat α - and β -adducin-encoding genes. Gene, 1995, 166, 307-311.	2.2	19
80	Genomic organisation and chromosomal localisation of the gene encoding human beta adducin. Gene, 1995, 167, 313-316.	2.2	19
81	Binding of nuclear factors to a satellite DNA of retroviral origin with marked differences in copy number among species of the rodent <i>Ctenomys</i> . Nucleic Acids Research, 1994, 22, 656-661.	14.5	13
82	DNA sequencing by the chemical method: a 10 minute procedure for the G+A reaction. Trends in Genetics, 1993, 9, 337-338.	6.7	13
83	The CRE-binding factor ATF-2 facilitates the occupation of the CCAAT box in the fibronectin gene promoter. FEBS Letters, 1993, 327, 25-28.	2.8	24
84	<i>Neurospora crassa</i> cDNA clones coding for a new member of the serpin family. FEBS Letters, 1990, 273, 103-106.	2.8	17